A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

This Phase 3 study is testing whether a drug called pegcetacoplan (which targets part of the immune system called complement) can prevent a complication called delayed graft function (DGF) — where a transplanted kidney is slow to start working — in high-risk kidney transplant recipients. **You may be eligible if...** - You have end-stage kidney disease, are on dialysis (for at least 3 months), and produce very little urine - You are waiting for your first or second kidney transplant from a deceased donor - Your antibody levels (CPRA) are below 50%, meaning rejection risk is lower - You are considered low-to-moderate rejection risk by your transplant team **You may NOT be eligible if...** - You are receiving a living donor kidney transplant - This is your third or more kidney transplant - Your prior transplant failed due to serious infection or blood clot - You have high levels of donor-specific antibodies Talk to your doctor to see if this trial is right for you.